160 related articles for article (PubMed ID: 35803770)
1. A Role of Non-FDG Tracers in Lung Cancer?
Novruzov E; Mori Y; Antke C; Dabir M; Schmitt D; Kratochwil C; Koerber SA; Haberkorn U; Giesel FL
Semin Nucl Med; 2022 Nov; 52(6):720-733. PubMed ID: 35803770
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Alternative and New Radiopharmaceutical Agents for Lung Cancer.
Telo S; Calderoni L; Vichi S; Zagni F; Castellucci P; Fanti S
Curr Radiopharm; 2020; 13(3):185-194. PubMed ID: 31868150
[TBL] [Abstract][Full Text] [Related]
4. New tracers beyond FDG in head and neck oncology.
Gornik G; Weber W
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):529-40. PubMed ID: 22019710
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
6. Imaging in lung cancer: positron emission tomography scan.
Vansteenkiste JF
Eur Respir J Suppl; 2002 Feb; 35():49s-60s. PubMed ID: 12064681
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
8. FDG PET Hybrid Imaging.
Becker J; Schwarzenböck SM; Krause BJ
Recent Results Cancer Res; 2020; 216():625-667. PubMed ID: 32594401
[TBL] [Abstract][Full Text] [Related]
9. Non-Small-Cell Lung Cancer PET Imaging Beyond F18 Fluorodeoxyglucose.
Cheng G
PET Clin; 2018 Jan; 13(1):73-81. PubMed ID: 29157387
[TBL] [Abstract][Full Text] [Related]
10. Role of
Delgado Bolton RC; Calapaquí-Terán AK; Giammarile F; Rubello D
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(4):229-233. PubMed ID: 31202725
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography and computed tomography with [
Pang Y; Zhao L; Shang Q; Meng T; Zhao L; Feng L; Wang S; Guo P; Wu X; Lin Q; Wu H; Huang W; Sun L; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1322-1337. PubMed ID: 34651226
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose.
Zhu J; Pan F; Cai H; Pan L; Li Y; Li L; Li Y; Wu X; Fan H
Front Med (Lausanne); 2022; 9():945602. PubMed ID: 36275809
[TBL] [Abstract][Full Text] [Related]
13. Tumorous tissue characterization using integrated 18F-FDG PET/dual-energy CT in lung cancer: Combining iodine enhancement and glycolytic activity.
Martin SS; Muscogiuri E; Burchett PF; van Assen M; Tessarin G; Vogl TJ; Schoepf UJ; De Cecco CN
Eur J Radiol; 2022 May; 150():110116. PubMed ID: 34996651
[TBL] [Abstract][Full Text] [Related]
14. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
15. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography in the management of non-small cell lung cancer.
Vansteenkiste JF; Stroobants SG
Hematol Oncol Clin North Am; 2004 Feb; 18(1):269-88. PubMed ID: 15005293
[TBL] [Abstract][Full Text] [Related]
17.
Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
[TBL] [Abstract][Full Text] [Related]
18. Present and future roles of FDG-PET/CT imaging in the management of lung cancer.
Kitajima K; Doi H; Kanda T; Yamane T; Tsujikawa T; Kaida H; Tamaki Y; Kuribayashi K
Jpn J Radiol; 2016 Jun; 34(6):387-99. PubMed ID: 27121156
[TBL] [Abstract][Full Text] [Related]
19. Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI.
Ohno Y; Yoshikawa T; Takenaka D; Koyama H; Aoyagi K; Yui M; Oshima Y; Hamabuchi N; Tanaka Y; Shigemura C; Oota S; Nomura M; Murayama K; Inui Y; Kikukawa K; Toyama H
AJR Am J Roentgenol; 2022 May; 218(5):899-908. PubMed ID: 34877872
[No Abstract] [Full Text] [Related]
20. Enhanced glucose metabolism mediated by CD147 is associated with
Zhang Y; Liu J; Sun Y; Yu X; Wang J; Dai D; Zhu Y; Song X; Zhu L; Li X; Xu W
Thorac Cancer; 2020 May; 11(5):1245-1257. PubMed ID: 32162491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
